{
  "docId": "019de071-fee7-744f-89ad-50de02e7ef2c",
  "docSlug": "b5a336d0fe4b7b554c90c4664e01c224",
  "documentTitle": "Comera | SPAC Presentation Deck | 33 slides",
  "authorId": "comera",
  "authorName": "Comera Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 33,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses an FDA pilot program as external validation of the industry-wide innovation gap.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-fee7-744f-89ad-50de02e7ef2c/15",
  "deckHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c",
  "deckJsonHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c.json",
  "deckAnchorHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.48,
        "x": 0.48,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Lack of innovation highlighted by FDA Novel Excipient Review Pilot Program. First proposals accepted December 2021",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "488a6936-60cc-4b25-8bc0-3ad1f7e89eea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.74,
        "x": 0.13,
        "y": 0.87
      },
      "kind": "callout",
      "text": "Excipients are substances added to a therapeutic agent in a drug formulation to aid in manufacturing, delivery, stability and/or patient acceptability",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3c769c2-998e-415e-b075-613ffd1eb330",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.04,
        "y": 0.34
      },
      "kind": "list",
      "text": "Suboptimal excipients can: Fail to reduce viscosity sufficiently; Destabilize the biologic protein; Increase injection pain; Cause other side effects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a13b5f21-6355-41d1-be45-022bc73dd712",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.5,
        "y": 0.61
      },
      "kind": "paragraph",
      "text": "The Center for Drug Evaluation and Research (CDER) has launched the voluntary Novel Excipient Review Pilot Program (Pilot Program), which is intended to allow excipient manufacturers to obtain FDA review of certain novel excipients prior to their use in drug formulations.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55a39b59-b991-4622-9f11-ed3e8cb98932",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Despite decades of research, a lack of effective excipients remains",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f04fee50-b3f2-44b5-9ff8-fb950a29cadb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Excipients Typically Used to Reduce Viscosity, but Lack of Innovation has Plagued Industry",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4dc19f7-5ec2-4eab-b928-ab6cc8bba362",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 11,
      "beatId": "09fad070-ba17-4e7f-a111-4048472e079d",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents the limitations of current biologics administration methods and the challenges of subcutaneous administration.",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c6c8959e-0df8-451d-bcaf-2620db15900d",
      "evidence": "The deck presents the limitations of current administration methods and the challenges of subcutaneous administration.",
      "position": 0,
      "objective": "What are the limitations of current biologics administration methods?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}